Avsplus Pharma Private Limited - Due diligence report

A 360° intelligence report on Avsplus Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and …

2021-03-11 Mumbai, Maharashtra Active Unlisted
Share
AP Avsplus Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Avsplus Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
78/100
Trust Score
Low Risk

Avsplus Pharma Private Limited is assessed as Low Risk with a Trust Score of 78/100. Avsplus Pharma Private Limited is an active private limited indian non-government company incorporated in 2021, operating in the Pharma sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Avsplus Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
78/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
35/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
70/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 3 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 35/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 1 open (15.00 cr) · 1 satisfied (4.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others2 48.0 cr
Compliance Score: 75/100 Low Risk
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2023 - filings overdue.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 85/100
NameDIN / PANDesignationAppointedTenureDIN status
KALPESH PRAKASHCHAND JAIN 01234567 Director 01/04/2018 6 yrs Approved
YOGENDRA GANGARAM MUNGALE 01234567 Director 01/04/2018 6 yrs Approved
DEEPESH DEEPAK KOLGE 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • 2 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
4 allotment(s) · 2 transfer(s)

Promoters hold a majority stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 65 · Distress 70
Growth signals & trust indicators
Latest year revenue grew 2.1x.
Asset base grew 24% - capacity expansion.
Operating for 5 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 0.86 in a year.
Statutory filings appear overdue.
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence74/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment58/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 15.00 cr already registered.
  • Compliance record supports lending.
Investor view74/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
09 May 2024
Director ceased
AJIT ANIL MANE
Director ceased
VIJAY DINKAR MOHITE
20 Dec 2023
Charge satisfied
Others
30 Sep 2023
Last AGM held
Annual general meeting
10 May 2023
Director ceased
MAYUR MULCHAND SHAH
Director ceased
ANAGHA BIPIN NACHANE
31 Mar 2023
Share transfer (FY 2023)
2000.00000000 shares to BIPIN ANAGHA NACHANE
Share transfer (FY 2023)
2000.00000000 shares to DEEPESH DEEPAK KOLGE
Latest balance sheet
Filed with ROC
30 Jan 2023
Charge created
Others - 15.00 cr
11 Jan 2023
Securities allotted
312501 Equity Shares - 5.00 cr raised
21 Sep 2022
Director appointed
DEEPESH DEEPAK KOLGE (Director)
11 Apr 2022
Director ceased
URVASHI SHARAD MISTRY
30 Nov 2021
Charge created
Others - 4.00 cr
09 Apr 2021
Securities allotted
4000 Equity Shares - 40,000.00 raised
10

Key Observations

Auto-generated from the data above
Debt-to-equity stands at 61% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 4 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Tricos Dermatologics Private Limited U74999MH2008PTC187712 Mumbai, Maharashtra, India
Colmed U33100MH2010PTC201959 Mumbai, Maharashtra, India
Rockwood Industries Private Limited U25111DL2006PTC149013 Delhi, Delhi, India
Surbhi Telelink Private Limited U74899DL2001PTC109285 New Delhi, Delhi, India
Shri Vardhman Tube Co. Private Limited U51909TN2010PTC179837 Tondiarpet Fort St George, Tamil Nadu, India
Ssm Formulations Private Limited U24233MH2012PTC237383 Hinganghat, Maharashtra, India
424 Vivigo India Private Limited U51909KA2021PTC153721 Bangalore North, Karnataka, India
Rajlakshmi Ispat Pvt. Ltd. U46691WB2006PTC108318 Howrah, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Avsplus Pharma Private Limited before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Avsplus Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 35/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 65/100, margin trends, ownership structure and peer set for Avsplus Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 78/100, distress signals and MSME payment-delay disclosures - know whether Avsplus Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Avsplus Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Avsplus Pharma Private Limited an active company?

Avsplus Pharma Private Limited has MCA status “Active” with a compliance score of 75/100 (Low Risk).

Is Avsplus Pharma Private Limited financially healthy?

Avsplus Pharma Private Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Avsplus Pharma Private Limited?

Its overall Trust Score is 78/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Avsplus Pharma Private Limited?

Promoters hold a majority stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Avsplus Pharma Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Avsplus Pharma Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 75/100 (Low Risk).

Is it risky to lend to Avsplus Pharma Private Limited?

Its Credit Risk Score is 35/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.